Awareness could eliminate inequalities in cancer diagnoses

November 12, 2012

There are substantial inequalities in the stage at which cancer patients receive their diagnosis - a critical factor for cancer survival - a new study by the University of Cambridge reveals. The researchers found that age, sex and income as well as the type of cancer influenced the risk of a patient being diagnosed at an advanced stage of the disease. Eliminating these inequalities would help improve the chances of a cure for up to 5,600 patients with seven common cancers each year. The research was published today in the Annals of Oncology.

The scientists studied ten common types of cancer responsible for two-thirds of all new cancer diagnoses in England. They found that 5,600 patients with seven common cancers each year are diagnosed at a late stage of their illness because of inequalities.

Narrowing social differences in stage at diagnosis could benefit 2000 men with prostate cancer, 1300 patients with lung cancer, 1000 women with breast cancer and 700 patients with melanoma, who are currently diagnosed in advanced stage because of inequalities. There are also important potential gains for patients with three rarer cancers (endometrial, kidney and bladder cancer). During the study period, 2006-2010, there were no notable social inequalities in the risk of advanced stage at diagnosis for patients with bowel (colon or rectal) cancer and women with ovarian cancer.

The research shows that 1 out of every 9 patients with these seven cancers who are currently diagnosed in advanced stage could be diagnosed at an earlier stage. Most of the improvements seem to be achievable by better educating people about symptoms and signs of potential cancer that should prompt a consultation with a doctor.

"We know that earlier stage diagnosis of cancer is important - it dramatically improves the effectiveness of treatment and survival for many cancers," said lead author Dr Georgios Lyratzopoulos, a researcher of the University of Cambridge. "This study highlights the importance of awareness of cancer symptoms and how people of different social groups react to such symptoms. It provides evidence about which patient groups would benefit most from targeted campaigns to raise awareness of different cancers."

For the study, Cambridge researchers worked together with the NHS to examine data from the Eastern Cancer Registration and Information Centre (ECRIC), the English regional cancer registry with the most complete information on stage at diagnosis. (Statistics about the stage of diagnosis of common cancers has been difficult to come by in the past, but their availability is currently increasing across the UK.)

The investigators examined information on the stage at diagnosis of nearly 100,000 patients with any of ten different cancers, including the five most common cancers (lung, breast, prostate, colon and rectal cancer) and also bladder, kidney, ovarian, and endometrial cancer and melanoma (the most aggressive type of skin cancer). The analysis took account of different tumour sub-types and whether the cancer was detected through screening.

The potential for improving diagnosis was not the same across all cancers. Men with melanoma and lung cancer were more likely to be diagnosed at an advanced stage compared with women with the same cancer. Patients with breast, prostate and endometrial cancer and melanoma living in poorer neighbourhoods were more likely to be diagnosed at late stage compared with those living in less deprived neighbourhoods.

The researchers focused on examining variation in diagnosis by age among patients aged 65 or older, because 2/3 of all cancers occur in this age group and because of evidence of potential deficits in the care of older patients. They found that for four cancers (breast, prostate, melanoma and endometrial) older patients were more likely to be diagnosed at an advanced stage. However, for three other cancers (lung, bladder and renal cancer) the opposite was true, with older patients being less likely to be diagnosed at an advanced stage.

"For cancers where there is evidence that symptom awareness matters, such as breast, prostate, melanoma and endometrial cancer, older individuals are more likely to have their cancer discovered late. In contrast, for cancers which there is a good enough medical test, such as X-ray or ultrasound, it seems that being old can protect somewhat from late stage diagnosis - presumably because the frequency of having these tests increases with older age and infirmity," said Dr Lyratzopoulos.

Policy experts believe that deficiencies in both early diagnosis and optimal treatment may be responsible for poorer cancer survival in the UK compared with some other European countries with similar health care systems and robust statistics (e.g. Scandinavian countries). Regarding deficiencies in early diagnosis, delays in patients recognising symptoms and presenting to their doctors as well as delays by the health system could be responsible. The study highlights that differences in perceptions of cancer between patients may be more important than previously thought for at least some (although not all) types of cancer.

"Awareness campaigns about the symptoms of bowel and ovarian cancer have been launched relatively recently and future research should establish their effectiveness. Avoiding a patchy dissemination of awareness messages among different social groups is important to prevent future inequalities in early diagnosis and for such campaigns to have the maximum impact," said senior author Dr David Greenberg from ECRIC (the Eastern Cancer Registration and Information Centre).

The study was supported by the National Institute for Health Research and ECRIC.
-end-
For additional information please contact:

Genevieve Maul, Office of Communications, University of Cambridge
Tel: direct, 44-122-376-5542, 44-122-333-2300
Mob: 44-777-401-7464
Email: genevieve.maul@admin.cam.ac.uk

Dr Georgios Lyratzopoulos, Clinical Senior Research Associate and NIHR Post-Doctoral Fellow, Cambridge Centre for Health Service Research, University of Cambridge.
Tel: 44-780-359-1859 Email: gl290@medschl.cam.ac.uk

Notes to editors:

1. The paper 'Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer' will be published online on the 13th of November 2012 by Annals of Oncology. The paper is open access, and can be retrieved from the Advance Access page of the Journal: http://annonc.oxfordjournals.org/content/early/recent (see doi: 10.1093/annonc/mds526).

2. Diagnosing cancer earlier is a key objective of recent UK governments and of UK cancer charities, see http://www.cancerresearchuk.org/cancer-info/spotcancerearly/naedi/AboutNAEDI/ ; http://www.dh.gov.uk/health/category/policy-areas/nhs/cancer/

3. The study used data from the Eastern Cancer Registration and Information Centre (ECRIC), one of eight regional cancer registries in England http://ecric.nhs.uk/about

4. The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website.

University of Cambridge

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.